Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry

Background and Purpose— Although patients with atrial fibrillation (AF) who experienced an acute stroke are at high risk for recurrence, many patients are untreated or treated suboptimally for stroke prevention. The objective of this study is to compare clinical outcomes of AF patients with versus without previous stroke in relation to guideline-adherent antithrombotic treatment in a contemporary primary care population. Methods— Community cohort of 105 000 patients from 11 general practices in Darlington, England, was used to assess AF stroke prevention strategies against 2014 National Institute for Health and Care Excellence guidelines. Results— Overall, 2259 (2.15%) patients with AF were identified, of which 18.9% constituted a secondary prevention cohort. For secondary prevention, antithrombotic treatment was guideline adherent in 56.3%, 18.9% were overtreated, and 24.8% undertreated; corresponding proportions for primary prevention were 49.5%, 11.7%, and 38.8%, respectively. One-year stroke rates were 8.6% and 1.6% for secondary and primary prevention, respectively (P<0.001); corresponding all-cause mortality rates were 9.8% and 9.4%, respectively (P=0.79). On multivariable analysis, lack of antithrombotic treatment guideline adherence was associated with increased stroke risk for primary prevention (odds ratio, 2.95; 95% confidence interval, 1.26–6.90; P=0.013 for undertreatment); for secondary prevention, lack of guideline adherence was associated with increased risk of recurrent stroke (odds ratio, 2.80; 95% confidence interval, 1.25–6.27; P=0.012 for overtreatment) and all-cause death (odds ratio, 2.75; 95% confidence interval, 1.33–5.69; P=0.006 for undertreatment). Conclusions— Only approximately half of eligible patients with AF are prescribed oral anticoagulation in line with guidelines. Guideline-adherent antithrombotic treatment significantly reduces the risk of stroke among primary prevention patients and both risk of recurrent stroke and death in patients with previous stroke.

[1]  G. Lip,et al.  Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. , 2017, The American journal of medicine.

[2]  D. Lane,et al.  Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.

[3]  D. Fitzmaurice,et al.  Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF , 2016, European heart journal.

[4]  G. Lip,et al.  Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. , 2016, The American journal of medicine.

[5]  G. Lip,et al.  Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. , 2015, European heart journal.

[6]  G. Lip,et al.  Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  B. Gorenek,et al.  Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisi , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  G. Lip,et al.  Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors. , 2015, Journal of the American College of Cardiology.

[9]  J. Olesen,et al.  Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study , 2015, BMJ : British Medical Journal.

[10]  G. Lip,et al.  Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. , 2015, Progress in cardiovascular diseases.

[11]  P. Rothwell,et al.  Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study , 2015, The Lancet Neurology.

[12]  G. Lip,et al.  Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. , 2015, Age and ageing.

[13]  G. Lip,et al.  Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study , 2015, Circulation.

[14]  G. Lip,et al.  Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation , 2015, Circulation. Cardiovascular quality and outcomes.

[15]  F. Puisieux,et al.  Underuse of Oral Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in France: Comparisons of Resident Characteristics and Physician Attitude , 2015, Journal of the American Geriatrics Society.

[16]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[17]  Emily C. O'Brien,et al.  Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). , 2014, American heart journal.

[18]  M. Nobuyoshi,et al.  Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. , 2014, The American journal of cardiology.

[19]  A. Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[20]  Mukul Sharma,et al.  Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation , 2013, Thrombosis and Haemostasis.

[21]  D. Lane,et al.  Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial , 2013, Thrombosis and Haemostasis.

[22]  C. Gale,et al.  The use of anticoagulants in the management of atrial fibrillation among general practices in England , 2013, Heart.

[23]  J. Cornuz,et al.  Risk of falls and major bleeds in patients on oral anticoagulation therapy. , 2012, The American journal of medicine.

[24]  L. Fauchier,et al.  Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. , 2011, Chest.

[25]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[26]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[27]  S. Lévy,et al.  Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. , 2007, American heart journal.

[28]  K. Minematsu,et al.  Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  A. Waldo.  Stroke prevention in atrial fibrillation. , 2003, JAMA.

[30]  D. Lane.  Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors∗ , 2017 .

[31]  G. Lip,et al.  Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study , 2016, Clinical Research in Cardiology.

[32]  G. Lip,et al.  Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. , 2015, The British journal of general practice : the journal of the Royal College of General Practitioners.

[33]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[34]  Jennifer G. Robinson,et al.  ACCF/AHA TASK FORCE MEMBERS , 2013 .